Small Business: Cancer Immunotherapy Development – CII (11)
This special emphasis panel focuses on the many approaches to cellular therapy, including TILs, CAR- and TCR-engineered T cells, NK/NKT cells and their toxicities, as well as therapeutic combinations that employ adoptive and allogeneic cell transfer. It also covers the tumor vaccine development.
Review Dates
A roster for the panel will be posted here, at least 30 days prior to the review meeting
Topics
- Adoptive cellular therapies (TILs, CAR- and TCR-engineered T cells, NK/NKT cells) using immune cells as cancer treatment and their associated toxicities
- Cellular therapies including dendritic cells and mononuclear phagocytes
- Combination therapies that contain cell therapies
- Tumor vaccines of all types (protein/peptide, viral, DNA/RNA, dendritic cell, tumor cell) and formulations to induce or amplify tumor-specific immunity.
- Preclinical studies of combinations to improve the efficacy of immunotherapies
